Apitolisib is a potent oral pan-PI3K inhibitor belonging to the phosphoinositide 3-kinase class, primarily investigated for its therapeutic potential in treating various solid tumors, including breast,… Read more
Apitolisib is a potent oral pan-PI3K inhibitor belonging to the phosphoinositide 3-kinase class, primarily investigated for its therapeutic potential in treating various solid tumors, including breast, prostate, renal cell, and endometrial carcinomas. This category provides access to high-quality reference standards of Apitolisib, including its active pharmaceutical ingredient, related pharmacopeial and non-pharmacopeial impurities, and relevant metabolites. Additionally, stable isotope-labelled compounds are available to support precise analytical testing, method validation, and rigorous quality control protocols. Laboratories utilize these materials for impurity profiling, ensuring accurate identification and quantification of degradation products or synthesis-related byproducts throughout the drug development lifecycle. By relying on characterized standards, researchers can maintain the analytical integrity required for regulatory compliance and safety assessments in the development of cancer therapeutics.